Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer

Krastan B. Blagoev; Roumen Iordanov; Mengxi Zhou; Tito Fojo; Susan E. Bates

doi:10.18632/oncotarget.27855

Oncotarget

Oncotarget (a primarily oncology-focused, peer-reviewed, open access journal) aims to maximize research impact through insightful peer-review; eliminate borders between specialties by linking different fields of oncology, cancer research and biomedical sciences; and foster application of basic and clinical science.

Its scope is unique. The term "oncotarget" encompasses all molecules, pathways, cellular functions, cell types, and even tissues that can be viewed as targets relevant to cancer as well as other diseases. The term was introduced in the inaugural Editorial, Introducing Oncotarget.

As of January 1, 2022, Oncotarget has shifted to a continuous publishing model. Papers will now be published continuously within yearly volumes in their final and complete form and then quickly released to Pubmed.

Subscribe to receive alerts once a paper has been published by Oncotarget.

Impact Journals, LLC is the publisher of Oncotarget: www.impactjournals.com.

Impact Journals is a member of the Wellcome Trust List of Compliant Publishers.

Impact Journals is a member of the Society for Scholarly Publishing.

On December 23, 2022, Oncotarget server experienced a DDoS attack. As a result, Oncotarget site was inaccessible for a few hours. Oncotarget team swiftly dealt with the situation and took it under control. This malicious action will be reported to the FBI.

Research Papers:

Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer

Krastan B. Blagoev _, Roumen Iordanov, Mengxi Zhou, Tito Fojo and Susan E. Bates

PDF | Full Text | How to cite | Press Release

Oncotarget. 2021; 12:15-21. https://doi.org/10.18632/oncotarget.27855

Metrics: PDF 1103 views | Full Text 3744 views | ?

Abstract

Krastan B. Blagoev1^,2, Roumen Iordanov3, Mengxi Zhou4^,5, Tito Fojo4^,5 and Susan E. Bates4^,5

1 National Science Foundation, Alexandria, VA 22230, USA

2 Department of Biophysics, Johns Hopkins University, Baltimore, MD 21218, USA

3 Jackson Memorial Hospital, Department of Internal Medicine, Miami, FL 33136, USA

4 Department of Medicine, Division of Hematology/Oncology, Columbia University Medical Center, New York, NY 10032, USA

5 James J. Peters Veterans Affairs Medical Center, Bronx, NY 10032, USA

Correspondence to:

Krastan B. Blagoev,

email:

[email protected]

Keywords: drug resistance; metastatic prostate cancer; exponential growth; tumor kinetics; cancer stem cells

Received: September 23, 2020 Accepted: November 12, 2020 Published: January 05, 2021

Copyright: © 2021 Blagoev et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Most metastatic cancers develop drug resistance during treatment and continue to grow, driven by a subpopulation of cancer cells unresponsive to the therapy being administered. There is evidence that metastases are formed by phenotypically plastic cancer cells with stem-cell like properties. Currently the population structure and growth dynamics of the resulting metastatic tumors is unknown. Here, using scaling analysis of clinical data of tumor burden in patients with metastatic prostate cancer, we show that the drug resistant, metastasis-causing cells (MCC) are capable of producing drug resistant, exponentially growing tumors, responsible for tumor growth as a patient receives different treatments.

All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 27855

Publication Alerts

Research Papers:

Drug resistant cells with very large proliferative potential grow exponentially in metastatic prostate cancer

Abstract